Keros Therapeutics Inc (KROS) concluded trading on Wednesday at a closing price of $10.42, with 13.6 million shares of worth about $141.7 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.03% during that period and on January 15, 2025 the price saw a loss of about -16.51%. Currently the company’s common shares owned by public are about 39.26M shares, out of which, 32.86M shares are available for trading.
Stock saw a price change of -34.22% in past 5 days and over the past one month there was a price change of -43.46%. Year-to-date (YTD), KROS shares are showing a performance of -34.18% which decreased to -80.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.22 but also hit the highest price of $73.00 during that period. The average intraday trading volume for Keros Therapeutics Inc shares is 977.60K. The stock is currently trading -33.99% below its 20-day simple moving average (SMA20), while that difference is down -74.90% for SMA50 and it goes to -79.16% lower than SMA200.
Keros Therapeutics Inc (NASDAQ: KROS) currently have 39.26M outstanding shares and institutions hold larger chunk of about 83.33% of that.
The stock has a current market capitalization of $422.09M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$5.21 in the same period. It has Quick Ratio of 19.03 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KROS, volatility over the week remained 8.82% while standing at 7.28% over the month.
Stock’s fiscal year EPS is expected to rise by 0.22% while it is estimated to increase by 3.14% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on December 16, 2024 offering an Outperform rating for the stock and assigned a target price range of between $102 and $63 to it. Stock get a Hold rating from TD Cowen on December 12, 2024.
